Alisertib (MLN8237)

製品コードS1133

Alisertib (MLN8237)化学構造

分子量(MW):518.92

Alisertib (MLN8237)は一種の選択性オーロラ(Aurora )A阻害剤で、無細胞試験でIC50値が1.2 nMです。Alisertib (MLN8237)はオーロラAに作用する選択性はオーロラ Bに作用する選択性より200倍以上が高くなります。臨床3期。

サイズ 価格 在庫  
USD 211 あり
USD 151 あり
USD 264 あり
USD 844 あり

文献中の引用(48)

カスタマーフィードバック(12)

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017.. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

製品安全説明書

Aurora Kinase阻害剤の選択性比較

生物活性

製品説明 Alisertib (MLN8237)は一種の選択性オーロラ(Aurora )A阻害剤で、無細胞試験でIC50値が1.2 nMです。Alisertib (MLN8237)はオーロラAに作用する選択性はオーロラ Bに作用する選択性より200倍以上が高くなります。臨床3期。
特性 First orally available inhibitor of Aurora A.
ターゲット
Aurora A [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
1.2 nM 396.5 nM
体外試験

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[wMlUh|ryP MUS3NkBp M4rNU2ROW09? NULLb5N1UUN3ME2wMlA1KM7:TR?= MUOyOlE{PjZ6NB?=
LS174T M4r2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV2wMlUh|ryP Mn32O|IhcA>? NFHZS4tFVVOR NF\3XHlKSzVyPUCuNFUh|ryP MXyyOlE{PjZ6NB?=
T84 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\XNE42KM7:TR?= M2Hoe|czKGh? MYPEUXNQ M3y4dmlEPTB;MD6wPUDPxE1? MUSyOlE{PjZ6NB?=
LS180 M1fiRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGwMlUh|ryP MkmwO|IhcA>? NH;DOI1FVVOR NWX1cGxYUUN3ME2xJO69VQ>? MmLxNlYyOzZ4OES=
SW948 NEDkU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HoR|AvPSEQvF2= M2f2clczKGh? NHv4XnNFVVOR NHzqTWtKSzVyPUGg{txO MUmyOlE{PjZ6NB?=
HCT15 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rhd|AvPSEQvF2= MmK2O|IhcA>? MUXEUXNQ NIj3VWZKSzVyPECuOEDPxE1? MYmyOlE{PjZ6NB?=
DLD-1 NYrqXYpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnONE42KM7:TR?= M1TyTVczKGh? MUfEUXNQ MYfJR|UxRDBwODFOwG0> M3XB[FI3OTN4Nki0
MIP-101 NU\s[IFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;NNE42KM7:TR?= NHKxN484OiCq M1nTemROW09? M3HVWGlEPTB;MTFOwG0> MWiyOlE{PjZ6NB?=
SNU1544 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4X1flAvPSEQvF2= MkDCO|IhcA>? NVrZUJp5TE2VTx?= M3jmWmlEPTB;MTFOwG0> MV2yOlE{PjZ6NB?=
OCI-Ly10 NH;hXGNEgXSxdH;4bYMhSXO|YYm= Mn3KO|IhcA>? Mo\FSG1UVw>? MYHJR|UxRTBwMEW4JO69VQ>? M3Tld|I2QDd6M{Ox
SU-DHL2 NXPtWXRFS3m2b4TvfIlkKEG|c3H5 NXLwcHpLPzJiaB?= M4DOT2ROW09? NWL5b45GUUN3ME2wMlAyKM7:TR?= NXrpeoZtOjV6N{izN|E>
OCI-LY7 M2LkSGN6fG:2b4jpZ{BCe3OjeR?= NYC0VXpjPzJiaB?= M3rLTWROW09? NIjoO4ZKSzVyPUCuNFgyKM7:TR?= NVTUVodZOjV6N{izN|E>
SU-DHL6 Ml\6R5l1d3SxeHnjJGF{e2G7 NX7VSXVPPzJiaB?= NFmxNpNFVVOR NYLwU|M6UUN3ME2wMlQ5OiEQvF2= MUKyOVg4QDN|MR?=
Jeko-1 M1jFVWN6fG:2b4jpZ{BCe3OjeR?= M2rvOVczKGh? Mnm2SG1UVw>? NUSxeWI1UUN3ME2wMlAzQSEQvF2= NXyyWo9oOjV6N{izN|E>
JVM-2 MYTDfZRwfG:6aXOgRZN{[Xl? MVe3NkBp NHTsdnlFVVOR M3u4fWlEPTB;MD6wNUDPxE1? NXjUc2lIOjV6N{izN|E>
Rec-1 NIjWe2xEgXSxdH;4bYMhSXO|YYm= M3PhdVczKGh? MV\EUXNQ NWXCUnFmUUN3ME2wMlA5PyEQvF2= MlPmNlU5Pzh|M{G=
Z-138 MUnDfZRwfG:6aXOgRZN{[Xl? NHH5OpQ4OiCq NH;F[XpFVVOR M13pbGlEPTB;MD6wNVMh|ryP NEDXO44zPTh5OEOzNS=>
H9 NHXNWJNEgXSxdH;4bYMhSXO|YYm= Ml;2O|IhcA>? MYHEUXNQ MV7JR|UxRTBwNjFOwG0> NV20TmpHOjV6N{izN|E>
HH Mo\6R5l1d3SxeHnjJGF{e2G7 NIPnSmg4OiCq M1jXPGROW09? NYHaZ4dtUUN3ME2wMlch|ryP NGfpe|gzPTh5OEOzNS=>
DND41 MUTDfZRwfG:6aXOgRZN{[Xl? NUjxfW12PzJiaB?= NGPDO3FFVVOR NFn6XZRKSzVyPUCuNUDPxE1? NIHFe|gzPTh5OEOzNS=>
CCL119 M4TNbWN6fG:2b4jpZ{BCe3OjeR?= NELNTJk4OiCq MnzISG1UVw>? M4nPSmlEPTB;MD6wOlIh|ryP NVXs[2pjOjV6N{izN|E>
J.Cam 1.6 MYfDfZRwfG:6aXOgRZN{[Xl? NGLhZXo4OiCq NYj3fWF6TE2VTx?= NWriPG1jUUN3ME2wMlExPSEQvF2= M1\DfVI2QDd6M{Ox
Sup-T1 NFnkPHJEgXSxdH;4bYMhSXO|YYm= MVS3NkBp MkfrSG1UVw>? NVvkdpYzUUN3ME2yMlE1OiEQvF2= M3myd|I2QDd6M{Ox
Tib 152 Mm[zR5l1d3SxeHnjJGF{e2G7 NXGxUplqPzJiaB?= MWfEUXNQ MmPZTWM2OD1yLkig{txO NViycmp2OjV6N{izN|E>
MCF7 MVnGeY5kfGmxbjDBd5NigQ>? M3faXVUh|ryP NXLpSGtnOjRiaB?= NIH1R2RFVVOR NGDCSm9KdmS3Y3XzJGczN01iYYLy[ZN1 NULaWms6OjV6M{S0NFE>
MDA-MB-231 MW\GeY5kfGmxbjDBd5NigQ>? NGLKNpk2KM7:TR?= NULuTGMzOjRiaB?= NGm5N2lFVVOR M1vZd2lv\HWlZYOgS|MwVSCjcoLld5Q> M4fuTVI2QDN2NECx
MCF7 NXuySGtDTnWwY4Tpc44hSXO|YYm= MYm1JO69VQ>? MYWyOEBp MXzEUXNQ M{XodGRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsyN0OGQ{K= M2T0fFI2QDN2NECx
MCF7 MkXLSpVv[3Srb36gRZN{[Xl? M13NXlUh|ryP MlzyNlQhcA>? NHLsbJFFVVOR M2TiXWRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz MnrYNlU5OzR2MEG=
MCF7 NXLj[2Z4TnWwY4Tpc44hSXO|YYm= NITZfoY2KM7:TR?= M3fZZ|I1KGh? NIPKU5ZFVVOR MUTE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiY4njcIlvKEJz NWLYPXptOjV6M{S0NFE>
MCF7 MlGzSpVv[3Srb36gRZN{[Xl? MYC1JO69VQ>? MYqyOEBp NGXsVnhFVVOR NFHIZZBKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFIyKFejZkGvR4lxOQ>? MoG4NlU5OzR2MEG=
MCF7 MXjGeY5kfGmxbjDBd5NigQ>? NVXIWGtMPSEQvF2= NEDWemozPCCq M1TB[mROW09? MVXJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEK3JGtqeDF? MnXyNlU5OzR2MEG=
MDA-MB-231 MoC3SpVv[3Srb36gRZN{[Xl? MUm1JO69VQ>? MoLSNlQhcA>? M1zBVmROW09? Mn;xSIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|EwS0SFMh?= M1z1[VI2QDN2NECx
MDA-MB-231 NGizZpNHfW6ldHnvckBCe3OjeR?= NYm5[4VuOSEQvF2= MUmyOEBp NFLNW49FVVOR NWHCR3pyUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzJ? M1rkNFI2QDN2NECx
MDA-MB-231 MVTGeY5kfGmxbjDBd5NigQ>? M1XJTVUh|ryP NVOyeXRtOjRiaB?= M2S1bmROW09? MVjE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiY4njcIlvKEJz MWOyOVg{PDRyMR?=
MDA-MB-231 MVLGeY5kfGmxbjDBd5NigQ>? NU\4bGNjPSEQvF2= NGPweWQzPCCq NIrHbZFFVVOR NGnWTmRKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFIyKFejZkGvR4lxOQ>? MknDNlU5OzR2MEG=
MDA-MB-231 NX[1[W5VTnWwY4Tpc44hSXO|YYm= NWHpZYlbPSEQvF2= MUKyOEBp NXnneoFzTE2VTx?= NISwXIZKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG= MVSyOVg{PDRyMR?=
MDA-MB-231 MknlSpVv[3Srb36gRZN{[Xl? M4q2UVUh|ryP MYSyOEBp MWjEUXNQ NX3NbGpLUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJA2Ow>? MnT0NlU5OzR2MEG=
MCF7 NVTtU5hqSXCxcITvd4l{KEG|c3H5 M3HadFUh|ryP MoDxNlQhcA>? NVHqRlZ[TE2VTx?= NH3Wb3FKdmS3Y3XzJIFxd3C2b4TpZ{Bl\WG2aB?= NF;uRmgzPTh|NESwNS=>
MDA-MB-231 M1XLfGFxd3C2b4Ppd{BCe3OjeR?= NUXzPXpDPSEQvF2= MlzkNlQhcA>? NV3hbnF5TE2VTx?= NV62U3g3UW6mdXPld{BieG:ydH;0bYMh\GWjdHi= NWL0R2s4OjV6M{S0NFE>
MCF7 M2rqUmZ2dmO2aX;uJGF{e2G7 NHXaNGMyKM7:TR?= NHi1SFQ4OiCq MWjEUXNQ M2jpcWlv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?= NIDGU3czPTh|NESwNS=>
MDA-MB-231 NELTTYJHfW6ldHnvckBCe3OjeR?= NWXnOVRpOSEQvF2= NX6xeHk6PzJiaB?= NF;idGdFVVOR M2P1UWlv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?= MnLiNlU5OzR2MEG=
U-2 OS NIPZbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWm1NEDPxE1? NEfDem8zPCCq MYTEUXNQ NVrvVpBEUUN3ME2xOk43KM7:TR?= NFPaWoozPTd7MkixNS=>
MG-63 M3vrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELO[YI2OCEQvF2= NIGwcIszPCCq M13ROmROW09? Ml\MTWM2OD17LkWg{txO MUiyOVc6OjhzMR?=
U-2 OS MX\BdI9xfG:|aYOgRZN{[Xl? Mn[wOUDPxE1? M1jyb|I1KGh? MnzWSG1UVw>? M2Pyd2lv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg> M1jqUVI2Pzl{OEGx
MG-63 MWLBdI9xfG:|aYOgRZN{[Xl? M4rIWVUh|ryP MWWyOEBp MonESG1UVw>? MV7JcoR2[2W|IHHwc5B1d3SrYzDj[YxtKGSnYYTo MmH5NlU4QTJ6MUG=
U-2 OS M4G3OmZ2dmO2aX;uJGF{e2G7 NEjQXIM2KM7:TR?= NXHqSHppOjRiaB?= M2DXUmROW09? NEPzboVRem:vb4Tld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? MYCyOVc6OjhzMR?=
MG-63 MUHGeY5kfGmxbjDBd5NigQ>? NH7BWI02KM7:TR?= NEPyWGMzPCCq NXrJOJpHTE2VTx?= M3vFR3Bzd22xdHXzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? NWrkd|BmOjV5OUK4NVE>
PANC-1 NHTSWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUm1NEDPxE1? MnXBNlQhcA>? MULEUXNQ MXnJR|UxRTdwMTFOwG0> MXWyOVY{OjJ{NR?=
BxPC-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYS1NEDPxE1? MkD5NlQhcA>? MXvEUXNQ NYGwdVhUUUN3ME22Mlgh|ryP Mor4NlU3OzJ{MkW=
PANC-1 NYPMXZpETnWwY4Tpc44hSXO|YYm= NHr2TnI2KM7:TR?= NYrUSHc4OjRiaB?= NFvHVZBFVVOR MXHJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJGczN01icHjhd4U> NX;1[Zp3OjV4M{KyNlU>
BxPC-3 M4P4WGZ2dmO2aX;uJGF{e2G7 NYGyeZlFPSEQvF2= MmHWNlQhcA>? NV31RXlWTE2VTx?= MnXuTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckBIOi:PIIDoZZNm NH\XXXMzPTZ|MkKyOS=>
PANC-1 NWrzRVY{TnWwY4Tpc44hSXO|YYm= NGX4b4I2KM7:TR?= M4O5[FI1KGh? NXy0c5M1TE2VTx?= MUjJcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> NFzvWI0zPTZ|MkKyOS=>
BxPC-3 MnjISpVv[3Srb36gRZN{[Xl? MnP6OUDPxE1? MWCyOEBp NFrKW5ZFVVOR MX7JcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> Ml3aNlU3OzJ{MkW=
SKOV3 NGfUeYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jVcFExOCEQvF2= NETVOIQzPCCq NFHUdFVFVVOR MlHnTWM2OD1{MD60PEDPxE1? MV[yOVYzPDd3MB?=
OVCAR4 NEK3cXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmxNFAh|ryP MknKNlQhcA>? MV\EUXNQ M{jOVmlEPTB;MkKuNVMh|ryP NWPPfVN[OjV4MkS3OVA>
SKOV3 NIjub|dHfW6ldHnvckBCe3OjeR?= NUjpSnBJPSEQvF2= NI\Bb484OiCq MU\EUXNQ NX;yR2VbUW6mdXPld{BIOi:PIHHydoV{fA>? M4TNd|I2PjJ2N{Ww
OVCAR4 NELjdJpHfW6ldHnvckBCe3OjeR?= MUO1JO69VQ>? NELkcFI4OiCq NWLs[FZuTE2VTx?= MnThTY5lfWOnczDHNk9OKGG{cnXzeC=> NXn5XW9zOjV4MkS3OVA>
SKOV3 NEHZTohCeG:ydH;zbZMhSXO|YYm= NG\NVZc2KM7:TR?= NHTrVY8zPCCq M3HYO2ROW09? M{TrUGlv\HWlZYOgZZBweHSxc3nz M3zzRVI2PjJ2N{Ww
OVCAR4 MnvNRZBweHSxc3nzJGF{e2G7 NVXWd2RnPSEQvF2= NELnT|IzPCCq MWPEUXNQ MlPKTY5lfWOnczDhdI9xfG:|aYO= NV:3XFBOOjV4MkS3OVA>
AGS NGLzbYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPBOIFoOjVizszN MVSyOEBp MXPEUXNQ NGnpbFVKSzVyPUG5MlA6KM7:TR?= NHr4RpUzPTZyOUmyNy=>
NCI-N78 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjWc3RPOjVizszN NYqwVVN{OjRiaB?= MoHBSG1UVw>? M4PYNmlEPTB;Mk[uN|Mh|ryP MXyyOVYxQTl{Mx?=
AGS MoXCRZBweHSxc3nzJGF{e2G7 MXi1JO69VQ>? NVXKSmJ3OjRiaB?= MmmzSG1UVw>? MnHxTY5lfWOnczDhdI9xfG:|aYO= Mn;ONlU3ODl7MkO=
NCI-N78 NXTHO3VCSXCxcITvd4l{KEG|c3H5 NXPkPZM5PSEQvF2= NUHkWXR4OjRiaB?= NXrTZ3RGTE2VTx?= NHrVd3BKdmS3Y3XzJIFxd3C2b4Ppdy=> MoKxNlU3ODl7MkO=
AGS MV3GeY5kfGmxbjDBd5NigQ>? MkPyOUDPxE1? M3\ocVI1KGh? M2PQV2ROW09? M1PxZWlv\HWlZYOgeIhmKGG3dH;wbIFogQ>? NYS0WVVlOjV4MEm5NlM>
NCI-N78 NGD1SVlHfW6ldHnvckBCe3OjeR?= NYHkOo1wPSEQvF2= NYLJN443OjRiaB?= NEfR[WdFVVOR MYHJcoR2[2W|IITo[UBifXSxcHjh[5k> MlrINlU3ODl7MkO=
HSC-3 Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml63NUDPxE1? MWW0PEBp NWTEbHhXUUN3ME2wMlU1KM7:TR?= NWfXVHdWOjV|Nk[xOFM>
GB30 M{nNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTKSllrOSEQvF2= MVi3JIQ> NWS3e25LTE2VTx?= Mn\PTWM2OD1yLkCxNUDPxE1? MWKyOVExPjR{OB?=
GB9 NIPXOHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[xJO69VQ>? NGDlXFM4KGR? NH3GNpJFVVOR M2TETmlEPTB;MD6wNlQh|ryP MoPFNlUyODZ2Mki=
GB169 NF;SSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TkW|Eh|ryP MmWxO{Bl NEnkUGVFVVOR NIH2fJVKSzVyPUCuNFMzKM7:TR?= M3jQUVI2OTB4NEK4
T24 M{XYNmZ2dmO2aX;uJGF{e2G7 MUSxJO69VQ>? M{HNfVQ5KGh? NX:0WY1MTE2VTx?= M1zNN2lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MkPMNlM1ODN4M{O=
RT4 M3XtXGZ2dmO2aX;uJGF{e2G7 NUDrTIhKOSEQvF2= Mn2xOFghcA>? M1iyfGROW09? Mlq5TY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= M2e5VlI{PDB|NkOz
UM-UC-3 MUHGeY5kfGmxbjDBd5NigQ>? MlnjNUDPxE1? MlfUOFghcA>? MVXEUXNQ Mk\VTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= NGfxc5czOzRyM{[zNy=>
T24 MkDFRZBweHSxc3nzJGF{e2G7 MnjmN{4yPiEQvF2= M{fFO|k3KGh? M4TheGROW09? MVnJR|UxRTBwMEOwOkDPxE1? M1nP[|I{PDB|NkOz
RT4 MkTURZBweHSxc3nzJGF{e2G7 M1rtZlMvOTZizszN MnK3PVYhcA>? M3\XNWROW09? NF\oflVKSzVyPUCuNVE6QCEQvF2= MmnINlM1ODN4M{O=
UM-UC-3 NHjnOoVCeG:ydH;zbZMhSXO|YYm= MWizMlE3KM7:TR?= NHXVUW06PiCq NXnER5I5TE2VTx?= MlLzTWM2OD1yLkC0OFkh|ryP M1fOZVI{PDB|NkOz
OVCAR-5 MnLkSpVv[3Srb36gRZN{[Xl? NETre202OCCwTR?= M33sNWlvcGmkaYTzJINmdGxibXnndoF1cW:w M17GeVI{OzN2M{K3
SKOV3ip2 NUT3cG14TnWwY4Tpc44hSXO|YYm= NGrZT|A2OCCwTR?= MkS4TY5pcWKrdIOgZ4VtdCCvaXfyZZRqd25? NIH2S2czOzN|NEOyOy=>
S462 NU\aR4xjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f3W|ExOCEQvF2= Mn7JO|IhcA>? MknySG1UVw>? NXvSXGg2SXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?= NUeySHlDOjN|MkixNVQ>
2884 NHPt[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TLNlExOCEQvF2= NW\LdZU3PzJiaB?= NWrH[m9YTE2VTx?= MnXIRZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? NITtNJkzOzN{OEGxOC=>
2885 NY[wOoduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fBOlExOCEQvF2= M3m1[FczKGh? MnqySG1UVw>? MVnBeJRmdnWjdHXzJINmdGxiZ4Lve5Rp MV2yN|MzQDFzNB?=
CRL-2396 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWCxNFAh|ryP M1v4XpdifGW{ M{D2U2lEPTB;MD6wPVIh|ryP M3HpSVI{OTV|NUK0
TIB-48 M3fmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH1NVAxKM7:TR?= MVH3ZZRmeg>? NI\6NIpKSzVyPUCuNFg5KM7:TR?= NHPVfoczOzF3M{WyOC=>
CRL-2396 MWfDfZRwfG:6aXOgRZN{[Xl? Mli0NUDPxE1? MVG0PEBp MmXMe4F1\XJ? MVvJcoR2[2W|IHHwc5B1d3Orcx?= MnuzNlMyPTN3MkS=
TIB-48 MVPDfZRwfG:6aXOgRZN{[Xl? MX:xJO69VQ>? NUHUXo9DPDhiaB?= NFezVJh4[XSnch?= NFexTHNKdmS3Y3XzJIFxd3C2b4Ppdy=> MoLwNlMyPTN3MkS=
AGS M17ZN2N6fG:2b4jpZ{BCe3OjeR?= MWiwMlUh|ryP M1O0d|I1KGh? M2n6WGROW09? MUnE[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? NWjRfpI5OjJ7N{K2NVE>
FLO-1 Mk\qR5l1d3SxeHnjJGF{e2G7 NYL3TYc{OC53IN88US=> NVKxUFFMOjRiaB?= NIrxN3lFVVOR NF;yWXRF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?= Mmr0NlI6PzJ4MUG=
OE33 MYjDfZRwfG:6aXOgRZN{[Xl? NXLHVVV4OC53IN88US=> NFTp[W0zPCCq MX\EUXNQ NGfQfoVF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?= MWOyNlk4OjZzMR?=
SKLMS NUKyZZBCS3m2b4TvfIlkKEG|c3H5 NWDzZ5ZoPzVibl2= NF3I[nI6PiCq NHHKSXlKdmS3Y3XzJIFxd3C2b4Ppdy=> MViyNlgzOTl7Nx?=
Leio285 MYXDfZRwfG:6aXOgRZN{[Xl? MYe3OUBvVQ>? MkLLPVYhcA>? NHjWNIRKdmS3Y3XzJIFxd3C2b4Ppdy=> M1fUZ|IzQDJzOUm3
Mes-Sa MWfDfZRwfG:6aXOgRZN{[Xl? MWW3OUBvVQ>? NF;mW5k6PiCq MmK2TY5lfWOnczDhdI9xfG:|aYO= NX7kXmkyOjJ6MkG5PVc>
DAOY MVHDfZRwfG:6aXOgRZN{[Xl? M{fFfFExKM7:TR?= MVe3NkBp NXOwOZFwTE2VTx?= MkXDTWM2OD1yLkC0JO69VQ>? M1fp[|IzPjZ7M{O1
IMR32 M13ITmN6fG:2b4jpZ{BCe3OjeR?= NX65fo1QOTBizszN NVXIWHJEPzJiaB?= M2m3bGROW09? M1mwbGlEPTB;MD6wN{DPxE1? M{S4SVIzPjZ7M{O1
Molt-4 NHLCSXlEgXSxdH;4bYMhSXO|YYm= MUCxNEDPxE1? MW[3NkBp NF;TVFhFVVOR M4n0OmlEPTB;MD6wNkDPxE1? M2XSfFIzPjZ7M{O1
MOLM-13 NYTldolST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXGzJO69VQ>? MnPuO|IhcA>? MXfEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MVyyNlQ5QDJ2OR?=
HL-60 NXjkZ5dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWzJO69VQ>? Mnv5O|IhcA>? NFTySJRFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MoHjNlI1QDh{NEm=
MV4-11 M4LJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGzJO69VQ>? M{XsOVczKGh? MXHEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NIW1XVYzOjR6OEK0PS=>
SKM-1 NHfuVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny5N{DPxE1? NIW3e2I4OiCq MWXEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NXvZfpNSOjJ2OEiyOFk>
SH2 M{TZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHsN{DPxE1? MUe3NkBp NVf4bJdPTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> NVviOoRJOjJ2OEiyOFk>
NOMO-1 MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHpS5k{KM7:TR?= M1nnOFczKGh? NVzHblc2TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> NUe4cXU2OjJ2OEiyOFk>
OCL-AML2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKzJO69VQ>? NIj3UJU4OiCq MULEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MViyNlQ5QDJ2OR?=
PL-21 NUPuV4JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkK4N{DPxE1? Mlq0O|IhcA>? MW\EbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MmDFNlI1QDh{NEm=
KG-1 NXTYOGQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDjN{DPxE1? NVLrUIRKPzJiaB?= NVjRcYJjTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> NUm0dZNqOjJ2OEiyOFk>
A172 MYDDfZRwfG:6aXOgRZN{[Xl? MYGxNFAh|ryP M2fkc|I1KGh? MVXEUXNQ MXXJR|UxRTBwMUKwJO69VQ>? MXKyNlI4PDN7OR?=
U87 M4Lw[GN6fG:2b4jpZ{BCe3OjeR?= NUPxXotXOTByIN88US=> MXSyOEBp NXj6ZoFxTE2VTx?= NWPkNXU6UUN3ME2wMlExPSEQvF2= MX6yNlI4PDN7OR?=
U251 M1XjZmN6fG:2b4jpZ{BCe3OjeR?= MYCxNFAh|ryP MYOyOEBp NV7MVJdGTE2VTx?= NUW0eXVYUUN3ME2wMlExOCEQvF2= M1zYZ|IzOjd2M{m5
T98 NFKwPFZEgXSxdH;4bYMhSXO|YYm= MVOxNFAh|ryP MU[yOEBp MVHEUXNQ NIruUWlKSzVyPUCuNVI2KM7:TR?= M1X2UlIzOjd2M{m5
LN18 MnO3R5l1d3SxeHnjJGF{e2G7 M4HNSFExOCEQvF2= M4nodlI1KGh? NYLCUlVbTE2VTx?= MUPJR|UxRTBwMkGwJO69VQ>? MkXyNlIzPzR|OUm=
LN443 NWfU[HgyS3m2b4TvfIlkKEG|c3H5 MoDSNVAxKM7:TR?= NYXld5NFOjRiaB?= NHzTZmdFVVOR MVvJR|UxRTBwMkKwJO69VQ>? MXuyNlI4PDN7OR?=
HF66 MYXDfZRwfG:6aXOgRZN{[Xl? MUCxNFAh|ryP MYeyOEBp MVHEUXNQ MW\JR|UxRTBwMkK1JO69VQ>? MmLtNlIzPzR|OUm=
HF2303 NWT1UmVFS3m2b4TvfIlkKEG|c3H5 MmDlNVAxKM7:TR?= MmnSNlQhcA>? NHewWG5FVVOR M2fSTmlEPTB;MD6wOlAh|ryP M2joclIzOjd2M{m5
HF2359 MlmzR5l1d3SxeHnjJGF{e2G7 M1HyWVExOCEQvF2= MVuyOEBp M323fmROW09? NF3OWVhKSzVyPUCuNFYxKM7:TR?= NVK5cIN2OjJ{N{SzPVk>
HF2414 NUj6SGVIS3m2b4TvfIlkKEG|c3H5 M3PJZ|ExOCEQvF2= NFThXpozPCCq M3\OWGROW09? MVnJR|UxRTBwMEiwJO69VQ>? MYmyNlI4PDN7OR?=
A-673 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nuTFExKM7:TR?= MXu5OkBp NXvuVHNiTE2VTx?= NU\jUXJRUUN3ME2wMlA{OiEQvF2= MYCyNVQ1QDV7MR?=
TC-32 MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXixNEDPxE1? M4DNOVk3KGh? NWTEUYpQTE2VTx?= MnrZTWM2OD1yLkCzPUDPxE1? M3qxZlIyPDR6NUmx
TC-71 NGrqdGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TlZ|ExKM7:TR?= M4Lxb|k3KGh? M3TacWROW09? MkXkTWM2OD1yLkGwNkDPxE1? MV[yNVQ1QDV7MR?=
SK-N-MC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;JclExKM7:TR?= NIjxOmc6PiCq M4HUeWROW09? M1\scWlEPTB;MD6wO|Ih|ryP MmDCNlE1PDh3OUG=
CHLA-9 MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO2cZVROTBizszN NGHaS3k6PiCq MVXEUXNQ MVnJR|UxRTBwMEG4JO69VQ>? M1XUe|IyPDR6NUmx
CHLA-10 M4XTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7LNVAh|ryP M1vzSVk3KGh? NYXVWFZFTE2VTx?= MnP6TWM2OD1yLkC2NEDPxE1? MVKyNVQ1QDV7MR?=
CHLA-25 NXvkUIxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\TUVExKM7:TR?= NUHN[Ys1QTZiaB?= Mn\jSG1UVw>? MoPuTWM2OD1yLkG2PEDPxE1? NYfod29FOjF2NEi1PVE>
CHLA-32 M{XINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j5OlExKM7:TR?= M3nLcFk3KGh? M1XlR2ROW09? Mn7kTWM2OD1yLkGzOkDPxE1? NYDsOG43OjF2NEi1PVE>
CHLA-56 M4L4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TueFExKM7:TR?= NEPGdmM6PiCq MXzEUXNQ MX3JR|UxRTFyIN88US=> NYi2T3lSOjF2NEi1PVE>
CHLA-258 M2r5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTDNVAh|ryP MV25OkBp MWrEUXNQ M3HLTGlEPTB;MD6xN|Ih|ryP NGO5RoEzOTR2OEW5NS=>
COG-E-352 NFXZN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn3ZYsyOCEQvF2= NWD3WYQ3QTZiaB?= Mn3FSG1UVw>? M{DaZmlEPTB;MD6wOFMh|ryP NETJV2ozOTR2OEW5NS=>
CHLA-90 M2rCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TZ[lExKM7:TR?= Mmq5PVYhcA>? M4j6V2ROW09? NXzWeYk1UUN3ME2wMlA3OSEQvF2= NInmcI8zOTR2OEW5NS=>
CHLA-119 Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LRR|ExKM7:TR?= Ml\LPVYhcA>? M1vpSmROW09? NFfxXYJKSzVyPUCuNFIzKM7:TR?= M2jQOVIyPDR6NUmx
CHLA-122 M17QPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nmd|ExKM7:TR?= MUS5OkBp MWjEUXNQ MX7JR|UxRTBwMEG5JO69VQ>? MXSyNVQ1QDV7MR?=
CHLA-136 NF;oSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\FNVAh|ryP Mo\XPVYhcA>? NV\4NVU6TE2VTx?= Ml3pTWM2OD1yLkCzPUDPxE1? NH\kV4EzOTR2OEW5NS=>
CHLA-140 NXPkPYJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe2[WJxOTBizszN MXy5OkBp M1v1dWROW09? Mn7ITWM2OD1yLkCyOkDPxE1? NHvuOWwzOTR2OEW5NS=>
LA-N-6 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX30VpFnOTBizszN MXG5OkBp MWjEUXNQ NYTYNYtTUUN3ME2wMlA2PCEQvF2= NYPTRmkzOjF2NEi1PVE>
NB-1643 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHl[WgyOCEQvF2= M2j6b|k3KGh? MYfEUXNQ MknqTWM2OD1yLkCzO{DPxE1? MojoNlE1PDh3OUG=
NB-EBc1 Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[x[HIyOCEQvF2= NHe5cmo6PiCq NH7W[mtFVVOR Ml7ZTWM2OD1yLkC1NEDPxE1? MoPSNlE1PDh3OUG=
SK-N-BE-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXexNEDPxE1? M{jC[|k3KGh? MkiwSG1UVw>? Mlf2TWM2OD1yLkCyPEDPxE1? MVWyNVQ1QDV7MR?=
SK-N-BE-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T4R|ExKM7:TR?= NUDMPHM4QTZiaB?= MYTEUXNQ M4OzZWlEPTB;MD6wN|Yh|ryP NF3IPZgzOTR2OEW5NS=>
SMS-KAN Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLueGoyOCEQvF2= NGjPWpI6PiCq Mn3pSG1UVw>? NUTF[HNRUUN3ME2wMlA{PCEQvF2= NYL2SHdVOjF2NEi1PVE>
SMS-KANR MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTZfpVEOTBizszN NXznN|ZJQTZiaB?= NEf0dndFVVOR NI[2R2JKSzVyPUCuNFI3KM7:TR?= M3i4d|IyPDR6NUmx
SMS-KCN MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M175R|ExKM7:TR?= NHfzNHE6PiCq MoXCSG1UVw>? MUHJR|UxRTBwMEG5JO69VQ>? MoPiNlE1PDh3OUG=
SMS-KCNR NVj0NItLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfMTpdOOTBizszN MVq5OkBp MYfEUXNQ MlPkTWM2OD1yLkCxNEDPxE1? Mo\tNlE1PDh3OUG=
SMS-LHN Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\nRpIyOCEQvF2= MXy5OkBp M2fucGROW09? NG[4PWVKSzVyPUCuNFMzKM7:TR?= MU[yNVQ1QDV7MR?=
SMS-MSN MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOxNEDPxE1? NXrHdFdvQTZiaB?= M{LW[WROW09? M3mze2lEPTB;MD6wNlIh|ryP NWTUVFJXOjF2NEi1PVE>
SMS-SAN MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHFNVAh|ryP MkezPVYhcA>? Mlm3SG1UVw>? MWDJR|UxRTBwMEKwJO69VQ>? NE\GN5MzOTR2OEW5NS=>
Granta-4 NX7rbGg{S3m2b4TvfIlkKEG|c3H5 MlrjNVAh|ryP MYi3JIQ> M3;OZ2lEPTB;MD6wOFAh|ryP MWiyNVI6OTh4Nx?=
DB MXHDfZRwfG:6aXOgRZN{[Xl? MX:xNEDPxE1? MYW3JIQ> NFrucI9KSzVyPUCuNFQzKM7:TR?= MVqyNVI6OTh4Nx?=
RL NX\jTYxGS3m2b4TvfIlkKEG|c3H5 M4i4OFExKM7:TR?= MUC3JIQ> MWPJR|UxRTBwMEG1JO69VQ>? M{XDWlIyOjlzOE[3
K562 NH72bVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULwPZR4OTBizszN M1nkWVk3KGh? M1jNOWlEPTB;MD6wPFch|ryP NYDxPWY{OjFyOUG2N|M>
LAMA-84 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDENWVvOTBizszN MoraPVYhcA>? M3XMbWlEPTB;MD6wOVch|ryP NFTYN5IzOTB7MU[zNy=>
MM15 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTlOEDPxE1? NYDTVFFVPzJiaB?= MUPEUXNQ MkLHTWM2OD1yLkGzJO69VQ>? NEXMPFUzODN6Mki0OC=>
OPM1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX4WJc1KM7:TR?= NWHoS|JVPzJiaB?= M1vK[GROW09? NHqwVotKSzVyPUCuNFMh|ryP MXuyNFM5Ojh2NB?=
RPM1 NYPjc5Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHPPFI1KM7:TR?= MnKzO|IhcA>? NXq4RpBkTE2VTx?= MWXJR|UxRTFyLkOyJO69VQ>? MoK4NlA{QDJ6NES=
INA6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXu0JO69VQ>? NFntSpE4OiCq NULIU3o3TE2VTx?= NFLENYlKSzVyPUCuNFAzKM7:TR?= NVL5eYp6OjB|OEK4OFQ>
OPM2 NYH3V3c6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUm0JO69VQ>? MUm3NkBp MoP4SG1UVw>? MlLlTWM2OD12LkO3JO69VQ>? NGHhN2EzODN6Mki0OC=>
MM1R M162UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVi4fm9PPCEQvF2= NF;KWVg4OiCq MXHEUXNQ MYfJR|UxRTFwNkig{txO NFXoeGYzODN6Mki0OC=>
DOX40 NXHpb5F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvmOEDPxE1? MVi3NkBp NUjSUIo4TE2VTx?= NEPseFlKSzVyPUWuOFgh|ryP MYCyNFM5Ojh2NB?=
LR5 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDaOYN[PCEQvF2= MVi3NkBp MkLVSG1UVw>? Mkm4TWM2OD1{LkWzJO69VQ>? NHnjOGszODN6Mki0OC=>
U266 NVew[2JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\wWZg1KM7:TR?= NVHySlJVPzJiaB?= MnrkSG1UVw>? MmjFTWM2OD1zLkSzJO69VQ>? NGfhZ48zODN6Mki0OC=>
RD Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSxNEDPxE1? MnftPVYhcA>? NHKxWIxKSzVyPUCuNlI5KM7:TR?= MmfYNlAyODh|M{i=
Rh41 NVq5fHdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHodVUyOCEQvF2= MlXKPVYhcA>? NX;wN|U4UUN3ME2wMlA6OCEQvF2= M1rNfFIxOTB6M{O4
Rh30 NUTZe4VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOxNEDPxE1? MX25OkBp NWDzUmJKUUN3ME2wMlI{OCEQvF2= MVGyNFExQDN|OB?=
BT-12 M{nGTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKxNEDPxE1? NHrNN4Y6PiCq M4TJcGlEPTB;MD6wOlAh|ryP MoPMNlAyODh|M{i=
CHLA-266 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q4OVExKM7:TR?= M3q0e|k3KGh? MmGzTWM2OD1yLkC3NkDPxE1? MYGyNFExQDN|OB?=
TC-71 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL4PVcyOCEQvF2= NHzGNHA6PiCq MU\JR|UxRTBwMUCyJO69VQ>? NE\KVo8zODFyOEOzPC=>
SJ-GBM2 M{S0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLDNZRPOTBizszN MmO1PVYhcA>? NELSXZdKSzVyPUCuNFUxKM7:TR?= MU[yNFExQDN|OB?=
NALM-6 NUjp[ItET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLUV|BiOTBizszN NVXZNGNmQTZiaB?= NFfa[VVKSzVyPUCuNFYzKM7:TR?= M17ObFIxOTB6M{O4
COG-LL-317 NHzUWoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37SPVExKM7:TR?= NFXCS5Y6PiCq NE\KRmhKSzVyPUCuNFQ4KM7:TR?= NGq4XHYzODFyOEOzPC=>
RS4-11 MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnLOJJnOTBizszN NXTUR3RIQTZiaB?= M{Dk[GlEPTB;MD6wNVgh|ryP NFvVdJQzODFyOEOzPC=>
MOLT-4 NHjUWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlviNVAh|ryP NH[3dos6PiCq MUXJR|UxRTBwMEK2JO69VQ>? NF31c5gzODFyOEOzPC=>
CCRF-CEM MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m0N|ExKM7:TR?= MVK5OkBp MV\JR|UxRTBwMEm0JO69VQ>? NHO5RZIzODFyOEOzPC=>
Kasumi-1 NUjmZZhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLFVIFuOTBizszN M2DMV|k3KGh? MVPJR|UxRTBwMUCzJO69VQ>? MknxNlAyODh|M{i=
Karpas-299 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz0NVAh|ryP NUfZbYRtQTZiaB?= NWrafGJPUUN3ME2wMlA{QCEQvF2= MYeyNFExQDN|OB?=
Ramos-RA1 M3:2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUexNEDPxE1? M2Tjb|k3KGh? MlPQTWM2OD1yLkGyO{DPxE1? NVTKO5dWOjBzMEizN|g>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
細胞試験: [2]
+ 展開
  • 細胞株: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 24, 48, and 72 hours
  • 実験の流れ: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • 製剤: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • 投薬量: ~30 mg/kg/day
  • 投与方法: Orally
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 27 mg/mL (52.03 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
体内 順序で溶剤を入れること:
15% Captisol
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 518.92
化学式

C27H20ClFN4O4

CAS No. 1028486-01-2
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • 回答:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase信号経路図

Aurora Kinase Inhibitors with Unique Features

相関Aurora Kinase製品

Tags: Alisertib (MLN8237)を買う | Alisertib (MLN8237) ic50 | Alisertib (MLN8237)供給者 | Alisertib (MLN8237)を購入する | Alisertib (MLN8237)費用 | Alisertib (MLN8237)生産者 | オーダーAlisertib (MLN8237) | Alisertib (MLN8237)化学構造 | Alisertib (MLN8237)分子量 | Alisertib (MLN8237)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID